PIK3CA Mutational Status Assessment

计划入组 100 人 · 首次发布于 2024 年 11 月 26 日

A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers

计划入组 30 人 · 首次发布于 2024 年 7 月 11 日

Trial of Taselisib in Overgrowth

计划入组 19 人 · 首次发布于 2017 年 9 月 21 日

PIK3CA

PI3Kalpha inhibitors (PIK3CA-related overgrowth spectrum)

RAS-PIK3CA inhibitor therapy(Vividion Therapeutics)

Inavolisib Shows Promise in PIK3CA-Mutated Advanced Solid Tumors

Inavolisib Receives FDA Priority Review for PIK3CA-Mutated Breast Cancer

Roche's Itovebi Plus Palbociclib and Fulvestrant Significantly Improves Progression-Free Survival in PIK3CA-Mutated Breast Cancer